Navigation Links
Tamoxifen does not adversely affect the brain

The breast cancer drug tamoxifen does not damage the brains of elderly women, alleviating fears of a neurotoxic effect of such treatment, recent study has revealed. According to researchers, tamoxifen has a similar effect on the brain to oestrogen, which has been linked with potentially neuroprotective action //against cognitive decline.

The researchers used proton magnetic resonance spectroscopy to determine levels of the cerebral metabolite myo-inositol, which has been found at elevated levels during brain injury, in the brains of 80 women. Sixteen of the women were breast cancer patients who had received tamoxifen therapy for at least two years beforehand, 27 were healthy women who had received preventative oestrogen-based hormone replacement therapy (HRT) for at least two years and 33 were healthy women who had received neither tamoxifen nor HRT.

Dr Ernst and colleagues found that women who had received tamoxifen or oestrogen had lower levels of myo-inositol than the controls who had received neither treatment. The women who had received tamoxifen for the longest period of time had the lowest levels of the metabolite present in their brains.

The researchers concluded that both tamoxifen and oestrogen may have neuroprotective effects, and may modulate the effect on the brain. They added that further research is needed to determine the effects of oestrogen and tamoxifen on cognition.
'"/>




Page: 1

Related medicine news :

1. Letrozole Beats Tamoxifen in Breast Cancer Therapy
2. Tamoxifen reduces breast cancer risk
3. Tamoxifen reduces breast cancer risk
4. Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence
5. Tamoxifen Ineffective In Presence Of Genetic Variation in Breast Cancer
6. New Drug More Effective than Tamoxifen in Preventing Breast Cancer Relapse
7. Raloxifene Better Than Tamoxifen For Breast Cancer
8. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
9. Study Identifies Mechanism Which May Help Tamoxifen Work Better
10. Tamoxifen Discontinuation Rates Surprisingly High
11. Tamoxifen Yields Long-term Reduction in Breast Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/18/2017)... ... 2017 , ... Hernandez Insurance Agencies, a northern Virginia firm ... DC region, is inaugurating a “New Leash On Life” charity initiative in conjunction ... to be companions for veterans in need. , The Semper K9 organization works ...
(Date:8/18/2017)... ... August 18, 2017 , ... MLM Insurance Group, a ... throughout southern Florida, is working to support the Take Stock In Children Foundation ... income families. , The Take Stock In Children Foundation (TSC) offers guidance and ...
(Date:8/18/2017)... ... 2017 , ... The Golseth Agency, a Texas based insurance management and financial ... regional charity campaign organized to provide support to Christina Upchurch and her two children ... and her children returned from out of town to find her husband passed away ...
(Date:8/18/2017)... ... 18, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... on false teachings pertaining to the mother of the Savior whom the world calls “Mother ... different picture of the role of this historical woman. , “The world bows, kisses ...
(Date:8/18/2017)... ... August 18, 2017 , ... 800response, the leading ... solutions, announced today the launch of a redesigned corporate website, 800response.com . ... fully responsive design, and an enhanced search directory for businesses and advertising agencies ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Inc., the creator of the drug Truveta for the treatment ... IPO. The United States spends approximately ... prescription epilepsy drug being $450.00-$1200.00 for a one month supply. ... AXIUM PHARMACEUTICALS, INC ... is the fact that Americans spent $42 billion on anxiety medications last ...
(Date:8/14/2017)... HACKENSACK, N.J. and PETACH TIKVAH, ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... for the second quarter ending June 30, 2017. ... advanced stages of preparing for our pivotal Phase 3 ... Chaim Lebovits , President and Chief Executive Officer ...
(Date:8/8/2017)...  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company ... results for the second quarter ended June 30, 2017. ... 2017 and to date: ... the Company,s lead project, BL-8040: Announced ... as novel stem cell mobilization treatment for autologous bone-marrow ...
Breaking Medicine Technology: